Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tenax Therapeutics ( (TENX) ) just unveiled an update.
On September 3, 2025, Tenax Therapeutics expanded its licensing agreement with Orion Corporation to gain exclusive worldwide rights to develop, commercialize, and manufacture orally-administered pharmaceutical products containing levosimendan. This amendment also includes provisions for Orion to supply levosimendan to Tenax, facilitating the development of these products and potentially strengthening Tenax’s position in the cardiovascular treatment market.
The most recent analyst rating on (TENX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Tenax Therapeutics stock, see the TENX Stock Forecast page.
Spark’s Take on TENX Stock
According to Spark, TipRanks’ AI Analyst, TENX is a Underperform.
Tenax Therapeutics’ overall score reflects substantial financial challenges due to an absence of revenue and consistent losses, heavily reliant on equity financing. Technical indicators suggest neutral momentum, but poor financial performance and valuation overshadow any potential stability.
To see Spark’s full report on TENX stock, click here.
More about Tenax Therapeutics
Tenax Therapeutics operates in the pharmaceutical industry, focusing on developing and commercializing pharmaceutical products. The company is particularly involved in products containing levosimendan, a compound used in cardiovascular treatments.
Average Trading Volume: 26,715
Technical Sentiment Signal: Hold
Current Market Cap: $27.35M
Find detailed analytics on TENX stock on TipRanks’ Stock Analysis page.